At a glance
- Originator Dompe Farmaceutici
- Class Osteoporosis therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fracture; Osteoporosis
Most Recent Events
- 14 Oct 2002 No development reported - Preclinical for Fracture treatment in Italy (PO)
- 07 Oct 2002 No development reported - Preclinical for Osteoporosis in Italy (PO)
- 20 Jun 2000 Preclinical development for Fracture treatment in Italy (PO)